Gemtuzumab ozogamicin

From WikiMD.org
Jump to navigation Jump to search

Gemtuzumab ozogamicin (pronunciation: gem-too-zoo-mab oh-zoh-ga-mye-sin) is a chemotherapeutic agent used in the treatment of acute myeloid leukemia (AML).

Etymology

The name "Gemtuzumab" is derived from "Gem" referring to gemtuzumab, the monoclonal antibody used in the drug, and "ozogamicin" referring to the antibiotic calicheamicin, which is the cytotoxic agent attached to the antibody.

Usage

Gemtuzumab ozogamicin is used as a targeted therapy for CD33-positive AML. CD33 is a protein found on the surface of these leukemia cells. The drug works by binding to the CD33 protein and delivering the cytotoxic agent directly to the leukemia cells, sparing healthy cells.

Related Terms

Side Effects

Like all chemotherapeutic agents, gemtuzumab ozogamicin can have side effects. These can include fever, nausea, and low blood cell counts. More serious side effects can include liver problems and infusion reactions.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski